Maynard Um
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c
-
-
-
-
-
-
-
FDA sets new PDUFA date for Capricor's Deramiocel therapy
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
B.Riley Reiterates Capricor (CAPR) at Buy, 'believe Deramiocel peak sales could likely exceed $1B'
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) call put ratio 1 call to 5.6 puts with a focus on November 2.5 puts
-
-
-
-
-
-
-
Capricor responds to FDA posting of Deramiocel rejection letter
-
-
-
-
-
-
-
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors
-
422,980 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

